ArticleJournal of immunology (Baltimore, Md. : 1950)2012
Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway.
Article in Journal of immunology (Baltimore, Md. : 1950), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 112 citations in OpenAlex.
- Dihydroartemisinin attenuates pemphigus vulgaris by regulating Dsg3 and the TLR9/NF-κB pathway.American journal of translational research · 2026Article
- Dihydroartemisinin Promotes N1 Polarization of Tumor-Associated Neutrophils and Enhances Their Anti-Tumor Activity via Hub Gene Modulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Dihydroartemisinin modulates the host proteome to suppress bovine viral diarrhea virus via mitochondrial and ER stress.Archives of microbiology · 2025Article
- Artemisinin and Its Derivatives from Molecular Mechanisms to Clinical Applications: New Horizons Beyond Antimalarials.International journal of molecular sciences · 2025Review
- Dihydroartemisinin enhances remyelination by switching microglia to the reparative phenotype.Journal of neuroinflammation · 2025Article
- Antimalarial Drug Artemotil Promotes Induction of Type 1 Regulatory T Cells.Inflammation · 2025Article
- Dihydroartemisinin decreases pre-existing neutralizing antibodies against adeno-associated virus in challenged mice.Frontiers in pharmacology · 2025Article
- Adjuvant Anti-tumor Therapy with Polyphenolic Compounds: A Review.Current medicinal chemistry · 2025Review
- Dihydroartemisinin inhibits follicular helper T and B cells: implications for systemic lupus erythematosus treatment.Archives of pharmacal research · 2024Article
- Review
- T helper cell 17/regulatory T cell balance regulates ulcerative colitis and the therapeutic role of natural plant components: a review.Frontiers in medicine · 2024Review
- Dihydroartemisinin ameliorates innate inflammatory response induced byJournal of pharmaceutical analysis · 2023Article
- Tehranolid and Artemisinin Effects on Ameliorating Experimental Autoimmune Encephalomyelitis by Modulating Inflammation and Remyelination.Molecular neurobiology · 2023Article
- Artemisinin derivative SM934 in the treatment of autoimmune and inflammatory diseases: therapeutic effects and molecular mechanisms.Acta pharmacologica Sinica · 2022Review
- Dihydroartemisinin beneficially regulates splenic immune cell heterogeneity through the SOD3-JNK-AP-1 axis.Science China. Life sciences · 2022Article
- Dihydroartemisinin regulates immune cell heterogeneity by triggering a cascade reaction of CDK and MAPK phosphorylation.Signal transduction and targeted therapy · 2022Article
- Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones.Molecules (Basel, Switzerland) · 2022Review
- Network Pharmacology-Based Exploration on the Intervention of Qinghao Biejia Decoction on the Inflammation-Carcinoma Transformation Process of Chronic Liver Disease via MAPK and PI3k/AKT Pathway.BioMed research international · 2022Article
- Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis.International journal of molecular medicine · 2022Article
- Dihydroarteannuin Ameliorates Collagen-Induced ArthritisFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Dihydroartemisinin (DHA) is an important derivative of the herb medicine Artemisia annua L., used in ancient China. DHA is currently used worldwide to treat malaria by killing malaria-causing parasites. In addition to this prominent effect, DHA is thought to regulate cellular functions, such as angiogenesis, tumor cell growth, and immunity. Nonetheless, how DHA affects T cell function remains poorly understood. We found that DHA potently suppressed Th cell differentiation in vitro. Unexpectedly, however, DHA greatly promoted regulatory T cell (Treg) generation in a manner dependent on the TGF-βR:Smad signal. In addition, DHA treatment effectively reduced onset of experimental autoimmune encephalomyelitis (EAE) and ameliorated ongoing EAE in mice. Administration of DHA significantly decreased Th but increased Tregs in EAE-inflicted mice, without apparent global immune suppression. Moreover, DHA modulated the mammalian target of rapamycin (mTOR) pathway, because mTOR signal was attenuated in T cells upon DHA treatment. Importantly, enhanced Akt activity neutralized DHA-mediated effects on T cells in an mTOR-dependent fashion. This study therefore reveals a novel immune regulatory function of DHA in reciprocally regulating Th and Treg cell generation through the modulating mTOR pathway. It addresses how DHA regulates immune function and suggests a new type of drug for treating diseases in which mTOR activity is to be tempered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.